Litcius/Paper detail

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

Foluso O. Ademuyiwa, Ina Chen, Jingqin Luo, Mothaffar F. Rimawi, Ian S. Hagemann, Bryan Fisk, Gejae Jeffers, Zachary L. Skidmore, Anamika Basu, Megan M. Richters, X. Cynthia, Katherine N. Weilbaecher, Jennifer L. Davis, Rama Suresh, Lindsay L. Peterson, Ron Bose, Nusayba A. Bagegni, Caron Rigden, Ashley Frith, Timothy P. Rearden, Leonel F. Hernandez‐Aya, Anna Roshal, Katherine Clifton, Mateusz Opyrchal, Olaronke Akintola-Ogunremi, Byung Ha Lee, Sara Ferrando‐Martínez, S. Church, Meenakshi Anurag, Matthew J. Ellis, Feng Gao, William E. Gillanders, Obi L. Griffith, Malachi Griffith

2021Breast Cancer Research and Treatment35 citationsDOIOpen Access PDF

Topics & Concepts

CarboplatinDocetaxelMedicineBreast cancerTriple-negative breast cancerOncologyInternal medicineChemotherapyGene signatureCancerImmunologyCisplatinBiologyGeneGene expressionBiochemistryBreast Cancer Treatment StudiesCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer Research